Menu
Giotrif® (afatinib) approved in Europe as new oral treatment option for patients with ...
- Approval provides a new oral treatment option for patients with the second largest sub-type of non-small cell lung cancer (NSCLC), representing approximately 20-30% of NSCLC cases
- Approval of Giotrif® is based on results of the LUX-Lung 8 study, which showed significantly improved overall survival and progression-free survival compared to Tarceva® (erlotinib) in patients with squamous cell carcinoma of the lung
- Afatinib is already approved in more than 60 countries for the treatment of patients with EGFR mutation-positive NSCLC*
(BUSINESS WIRE)-- Boehringer Ingelheim today announced that the http://me-newswire.net//news/17544/en...
Dans la même rubrique :
Vendredi 20 Juin 2025 - 08:00 Tchad : Coris Bank International Tchad lance officiellement sa marque |
Mardi 10 Juin 2025 - 10:30 Tchad : à Yamba-Tchingsou, une école officielle laissée pour compte |
Mercredi 4 Juin 2025 - 08:50 Tchad : Dans la province du Lac, le Projet PROLAC accélère la transformation locale |
